President & Founder

Anne has a background in the fields of dispute consulting, damage analysis and economic based research and modeling. She is a graduate of Boston University and Johns Hopkins University, with degrees in International Economics and Social Change & Development, and a graduate thesis on Human Rights. When her son was born with profound developmental delays, Anne left her career to gain expertise in Physical Therapy, Occupational Therapy, Speech Therapy and Behavioral Therapy to help her son to achieve developmental milestones. After a diagnosis of autism and ten years of intense therapeutic interventions, genetic testing showed a mutation on the MEF2C Gene. Anne established the US MEF2C Foundation to accelerate research and development to find treatments and a cure for our patients. She strongly believes that through collaborative efforts we can improve the lives of our patients and their families, Anne is honored to be an advocate for this special community.

Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai.

Dr. Friedman’s appointment in 2021 as Dean for Therapeutic Discovery at Mount Sinai recognizes his unique strengths in translating basic science into clinically meaningful advances, and his investigative work in liver disease has been instrumental in fueling the tremendous growth in emerging diagnostics and therapeutics for hepatic fibrosis. He is widely respected among commercial partners for his broad expertise from basic science to clinical trials, and currently consults for over 40 companies in the liver disease space.

Chen Familiy Associate Professor at Duke Univeristy, Durham, North Carolina

Dr. Bissig received his MD and PhD from the University of Bern School of Medicine & Natural Science, Bern, Switzerland. After completing his internal medicine fellowship, he moved to the US as a postdoctoral fellow in cancer biology and gene therapy at the Salk Institute for Biological Studies, La Jolla, California. During his education, he has maintained his vision of interdisciplinary research to improve human health. Dr. Bissig has continued to pursue his passion through his time at the Salk Institute and Baylor College of Medicine, where he started his own laboratory; and currently at Duke University where he creates therapeutic alternatives for children with metabolic diseases.